BAX vs BDX Stock Comparison: AI Score, Valuation, Performance and Upside
BAX (Baxter International) and BDX (Becton Dickinson) are both large diversified medical products companies serving hospitals — Baxter focuses on critical care consumables (IV fluids, renal care) and hospital equipment (through Hill-Rom), while BD covers medication delivery, diagnostics, and interventional products. Both have made major acquisitions creating integration complexity and elevated debt; both serve hospital systems with products that range from highly differentiated to commodity consumables.
BAX vs BDX is critical hospital consumables and smart bed equipment with recovery execution risk (Baxter's essential IV fluid position and Hill-Rom hospital equipment facing manufacturing disruption recovery and high post-acquisition debt) versus diversified medical technology with safety device regulatory moats and diagnostics installed base (BD's safety-engineered syringes mandated by OSHA, blood culture systems creating sticky laboratory revenue, and broad hospital product portfolio with simplification strategy) — critical consumables recovery story versus diversified med-tech with regulatory moats.
BAX holds the edge across 3 of 5 key metrics in this comparison. BAX leads on both 1-year return (+13.23%) and forward P/E quality (11.69x vs 13.38x for BDX), a relatively favorable combination of momentum and valuation. BDX leads on both revenue growth (5.40%) and operating margin (15.73%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BAX (+20.70%) than for BDX (+10.02%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- See Baxter's IV fluid market position and Hill-Rom smart hospital equipment as durable healthcare assets trading at a discount due to temporary Hurricane Helene disruption and elevated acquisition debt
- Believe Baxter's post-Vantive spinoff focus on hospital products simplifies the business and allows management attention on recovering IV production capacity and deleveraging the balance sheet
- Value the essential, inelastic nature of IV fluids (approximately 40% of U.S. hospital IV supply) as providing stable baseline demand regardless of healthcare spending trends
- Want a diversified medical technology company with regulatory moats from OSHA-mandated safety syringe requirements and a sticky diagnostics installed base generating recurring laboratory revenue
- Value BD's systematic divestiture and simplification strategy as improving operational focus and the quality of the remaining business over time
- Prefer BD's more stable, less disruption-prone revenue profile versus Baxter's recent operational challenges from manufacturing concentration and acquisition integration
| Metric | BAX | BDX |
|---|---|---|
| AI scorei | 27.0 | 41.0 |
| AI ranki | #2393 | #1044 |
| Latest closei | $25.76 | $193.76 |
| 1M returni | +8.65% | +4.22% |
| 3M returni | +10.32% | +21.15% |
| 6M returni | +42.01% | +25.15% |
| 1Y returni | +13.23% | +3.74% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BAX | BDX |
|---|---|---|
| 1Y ago | $11.21K (+12.1%) started 2025-10-16 | $10.46K (+4.6%) started 2025-10-16 |
| 5Y ago | $3.91K (-60.9%) started 2021-10-18 | $9.28K (-7.2%) started 2021-10-18 |
| 10Y ago | $7.26K (-27.4%) started 2016-10-17 | $14.87K (+48.7%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | BAX | BDX |
|---|---|---|
| Market capi | $12.3B | $48.44B |
| Trailing P/Ei | 87.85 | 30.77 |
| Forward P/Ei | 11.69 | 13.38 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 1.73 | 2.87 |
| Analyst targeti | $28.73 | $195.67 |
| Target upsidei | +20.70% | +10.02% |
| Metric | BAX | BDX |
|---|---|---|
| Revenue growthi | 5.30% | 5.40% |
| Earnings growthi | 36.80% | -31.40% |
| EPS growthi | +36.80% | -31.40% |
| FCF margini | +8.72% | +19.92% |
| Operating margini | 14.43% | 15.73% |
| Profit margini | -9.27% | 4.19% |
| ROIC proxyi | -14.37% | 6.61% |
| Return on equityi | -14.37% | 6.61% |
| Dividend yieldi | 0.17% | 2.36% |
| Payout ratioi | 154.67% | 72.49% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.59 | 0.28 |
| Debt/equityi | 156.45 | 68.84 |
| Current ratioi | 1.95 | 0.86 |
| Quick ratioi | 1.13 | 0.33 |
Over the past year, BAX and BDX have moved moderately in the same direction (correlation of 0.41), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BAX | BDX |
|---|---|---|---|
| 1Y | Growthi | +12.15% | +4.58% |
| CAGRi | +12.17% | +4.59% | |
| Volatilityi | 42.93% | 30.81% | |
| Sharpe ratioi | 0.38 | 0.16 | |
| Sortino ratioi | 0.52 | 0.21 | |
| Max drawdowni | 31.81% | 33.00% | |
| Current drawdowni | 9.14% | 7.74% | |
| Avg drawdowni | 14.84% | 15.44% | |
| Ulcer Indexi | 16.83% | 18.95% | |
| Max daily dropi | 15.99% | 17.22% | |
| Max wkly dropi | 21.52% | 16.86% | |
| 5Y | Growthi | -64.18% | -12.12% |
| CAGRi | -18.58% | -2.55% | |
| Volatilityi | 34.89% | 25.15% | |
| Sharpe ratioi | -0.54 | -0.15 | |
| Sortino ratioi | -0.69 | -0.20 | |
| Max drawdowni | 80.87% | 48.93% | |
| Current drawdowni | 68.81% | 29.68% | |
| Avg drawdowni | 51.92% | 18.30% | |
| Ulcer Indexi | 56.04% | 22.44% | |
| Max daily dropi | 22.42% | 18.13% | |
| Max wkly dropi | 24.85% | 20.00% | |
| 10Y | Growthi | -37.49% | +30.74% |
| CAGRi | -4.59% | +2.72% | |
| Volatilityi | 29.91% | 24.50% | |
| Sharpe ratioi | -0.16 | 0.05 | |
| Sortino ratioi | -0.20 | 0.07 | |
| Max drawdowni | 81.40% | 48.93% | |
| Current drawdowni | 69.68% | 29.68% | |
| Avg drawdowni | 30.23% | 13.07% | |
| Ulcer Indexi | 40.86% | 17.26% | |
| Max daily dropi | 22.42% | 18.13% | |
| Max wkly dropi | 24.85% | 20.00% |
| Category | BAX | BDX |
|---|---|---|
| Company | Baxter International Inc. | Becton, Dickinson and Company |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
| Core business | Baxter International provides critical care products for hospitals and patients — IV solutions and parenteral nutrition (the company produces approximately 40% of IV bags used in U.S. hospitals), peritoneal dialysis and hemodialysis products for kidney failure patients, acute care pharmaceuticals, and hospital equipment from its 2021 Hill-Rom acquisition (smart hospital beds, patient monitoring, nurse call systems). Baxter spun off its kidney care business as Vantive in 2024. | Becton Dickinson (BD) is a global medical technology company with three business segments: BD Medical (medication delivery including syringes, catheters, IV sets, drug delivery systems); BD Diagnostics (specimen collection, microbiology, laboratory automation); and BD Interventional (surgery, urology, peripheral intervention). BD is a leading manufacturer of safety-engineered syringes and needles, blood culture systems, and specimen collection devices. BD has completed major acquisitions including CareFusion (2015) and C.R. Bard (2017). |
| Investor focus | Investors track Baxter's hospital products revenue and margins, IV supply chain reliability (Baxter's manufacturing concentration in North Carolina was severely disrupted by Hurricane Helene in 2024), post-Hill-Rom integration execution, the Vantive kidney care spinoff impact, and debt reduction from high acquisition-related leverage. | Investors track BD's organic revenue growth across its three segments, margin expansion from efficiency programs, the Biosciences and Advanced Patient Monitoring spinoffs, and debt deleveraging from the C.R. Bard acquisition. BD has pursued a multi-year simplification strategy, divesting non-core businesses. |
- Critical IV fluids position in U.S. hospitals — Baxter produces approximately 40% of IV bags used in U.S. hospitals; IV fluids are an essential, inelastic hospital supply with no close substitute; this position creates durable revenue though at modest margins
- Hill-Rom smart hospital bed and patient monitoring integration — Hill-Rom's Progressa and Centrella smart beds and nurse call communication systems are sticky installed-base products that generate recurring service and upgrade revenue from hospitals committed to the platform
- Renal care expertise (through Vantive spinoff) developed over decades — Baxter pioneered peritoneal dialysis and built a global renal care franchise; the Vantive spinoff allows Baxter to focus on hospital products while Vantive pursues the kidney care market independently
- Market leadership in safety syringes and needlestick prevention — BD's Safety-Lok and other safety-engineered injection devices are mandated by OSHA needlestick prevention regulations; this regulatory driver creates mandatory demand for BD's products
- Blood culture and microbiology diagnostics installed base — BD's BACTEC blood culture systems and Phoenix antimicrobial susceptibility testing create a sticky diagnostics installed base in hospital laboratories; hospitals invested in BD platforms replace instruments with next-generation BD products
- Scale across medication delivery, diagnostics, and interventional — BD's breadth across multiple clinical care pathways diversifies revenue across hospital departments and creates cross-selling opportunities
- Hurricane Helene manufacturing disruption — Baxter's Marion, North Carolina facility (a major IV fluid production site) was severely damaged by Hurricane Helene in fall 2024, creating significant IV supply shortages across U.S. hospitals; the magnitude and duration of this disruption materially impacted Baxter's business and the U.S. healthcare system
- High debt burden from Hill-Rom acquisition — the $10.5B Hill-Rom acquisition created significant debt that Baxter must reduce through operating cash flow; high leverage constrains financial flexibility and creates earnings headwinds
- Hill-Rom integration complexity — combining Baxter's hospital products culture with Hill-Rom's smart hospital equipment business required significant operational integration; the combined company faces execution challenges across product portfolios
- Organic revenue growth execution — BD's complexity across numerous product lines and markets creates execution challenges; the company must demonstrate consistent mid-single-digit organic revenue growth to justify its valuation
- Currency headwinds — BD's large international business (~50% of revenue) creates significant foreign exchange translation risk; dollar strengthening reduces reported revenue and earnings meaningfully
- Innovation pipeline investment requirements — maintaining market leadership across syringes, diagnostics, and interventional requires ongoing R&D investment; BD must continually introduce next-generation products to prevent commoditization of its installed base
Compare more than two at a time
This page is a fixed writeup on BAX and BDX. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside BAX and BDX, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.